Request Demo
Last update 21 Mar 2025
NA-931
Last update 21 Mar 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms NA 931, NA931 |
Action agonists |
Mechanism GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with NA-931NCT06732245
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
NCT06564753
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition
NCT06615700
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NA-931 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus
100 Clinical Results associated with NA-931
Login to view more data
100 Translational Medicine associated with NA-931
Login to view more data
100 Patents (Medical) associated with NA-931
Login to view more data
100 Deals associated with NA-931
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Phase 3 | United States | - | |
| Diabetes Mellitus, Type 2 | Phase 1 | Australia | 06 May 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | zcemszodwk(sviyjjbywx) = dqlvivqusv hnmtvcohux (bvmudvjlxe ) View more | Positive | 07 Oct 2024 | |||
Placebo | zcemszodwk(sviyjjbywx) = mjusgptsqu hnmtvcohux (bvmudvjlxe ) | ||||||
Not Applicable | glucose | lipids | - | jrmbrujmsx(ubxycewfjk) = qucpskpeab cdbupcwulo (khfaqvwkym ) | Positive | 14 Jun 2024 | ||
NA-932 | jrmbrujmsx(ubxycewfjk) = mkxnjsovjj cdbupcwulo (khfaqvwkym ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free